Hasegawa Toshinori, Kato Takenori, Kida Yoshihisa, Hayashi Motohiro, Tsugawa Takahiko, Iwai Yoshiyasu, Sato Mitsuya, Okamoto Hisayo, Kano Tadashige, Osano Seiki, Nagano Osamu, Nakazaki Kiyoshi
Department of Neurosurgery, Komaki City Hospital, Komaki;
Department of Neurosurgery, Kamiiida Daiichi General Hospital, Nagoya;
J Neurosurg. 2016 Feb;124(2):403-10. doi: 10.3171/2015.3.JNS142677. Epub 2015 Sep 11.
The aim of this study was to explore the efficacy and safety of stereotactic radiosurgery for patients with facial nerve schwannomas (FNSs).
This study was a multiinstitutional retrospective analysis of 42 patients with FNSs treated with Gamma Knife surgery (GKS) at 1 of 10 medical centers of the Japan Leksell Gamma Knife Society (JLGK1301). The median age of the patients was 50 years. Twenty-nine patients underwent GKS as the initial treatment, and 13 patients had previously undergone surgery. At the time of the GKS, 33 (79%) patients had some degree of facial palsy, and 21 (50%) did not retain serviceable hearing. Thirty-five (83%) tumors were solid, and 7 (17%) had cystic components. The median tumor volume was 2.5 cm(3), and the median prescription dose to the tumor margin was 12 Gy.
The median follow-up period was 48 months. The last follow-up images showed partial remission in 23 patients and stable tumors in 19 patients. Only 1 patient experienced tumor progression at 60 months, but repeat GKS led to tumor shrinkage. The actuarial 3- and 5-year progression-free survival rates were 100% and 92%, respectively. During the follow-up period, 8 patients presented with newly developed or worsened preexisting facial palsy. The condition was transient in 3 of these patients. At the last clinical follow-up, facial nerve function improved in 8 (19%) patients, remained stable in 29 (69%), and worsened in 5 (12%; House-Brackmann Grade III in 4 patients, Grade IV in 1 patient). With respect to hearing function, 18 (90%) of 20 evaluated patients with a pure tone average of ≤ 50 dB before treatment retained serviceable hearing.
GKS is a safe and effective treatment option for patients with either primary or residual FNSs. All patients, including 1 patient who required repeat GKS, achieved good tumor control at the last follow-up. The incidence of newly developed or worsened preexisting facial palsy was 12% at the last clinical follow-up. In addition, the risk of hearing deterioration as an adverse effect of radiation was low. These results suggest that GKS is a safe alternative to resection.
本研究旨在探讨立体定向放射外科治疗面神经鞘瘤(FNS)患者的疗效和安全性。
本研究是一项多机构回顾性分析,对日本Leksell伽玛刀协会(JLGK1301)的10个医疗中心之一的42例接受伽玛刀手术(GKS)治疗的FNS患者进行分析。患者的中位年龄为50岁。29例患者将GKS作为初始治疗,13例患者此前曾接受过手术。在进行GKS时,33例(79%)患者有一定程度的面瘫,21例(50%)患者未保留有效听力。35例(83%)肿瘤为实性,7例(17%)有囊性成分。肿瘤中位体积为2.5 cm³,肿瘤边缘的中位处方剂量为12 Gy。
中位随访期为48个月。最后一次随访影像显示,23例患者部分缓解,19例患者肿瘤稳定。仅1例患者在60个月时出现肿瘤进展,但再次进行GKS导致肿瘤缩小。3年和5年无进展生存率分别为100%和92%。在随访期间,8例患者出现新发或原有面瘫加重。其中3例患者的病情为短暂性。在最后一次临床随访时,8例(19%)患者的面神经功能改善,29例(69%)患者保持稳定,5例(12%)患者恶化(4例患者为House-Brackmann III级,1例患者为IV级)。关于听力功能,20例治疗前纯音平均听阈≤50 dB的评估患者中,18例(90%)保留了有效听力。
GKS是原发性或残留性FNS患者的一种安全有效的治疗选择。所有患者,包括1例需要再次进行GKS的患者,在最后一次随访时均实现了良好的肿瘤控制。在最后一次临床随访时,新发或原有面瘫加重的发生率为12%。此外,作为放疗不良反应的听力恶化风险较低。这些结果表明,GKS是一种安全的手术替代方案。